This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Continuous Subcutaneous Delivery of Exenatide via ...

Continuous Subcutaneous Delivery of Exenatide via ITCA 650 Leads to Sustained Glycemic Control and Weight Loss for 48 Weeks in Metformin–Treated Subjects with Type 2 Diabetes

Read time: 1 mins
Published:25th Mar 2020
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest